AI-generated analysis. Always verify with the original filing.
Tonix Pharmaceuticals Holding Corp. announced two oral presentations on TONMYA TM at the ICCF, with the first presentation titled “Cyclobenzaprine HCl Sublingual. The announcement is furnished under Item 7.01 and reported under Item 8.01, with details in Exhibit 99.01.
Event Type
Disclosure
Voluntary
Variant
8-K
of this Current Report on Form 8-K, including Exhibit 99.01 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the United States Securit
Other Events. On March 10. 2026, the Company announced two oral presentations on TONMYA TM at the ICCF. The first presentation, “Cyclobenzaprine HCl Sublingual
Financial Statements and Exhibits. (d) Exhibit No. Description. 99.01 Press Release of the Company, March 10, 2026 104 Cover Page Interactive Data File (embedde